Evidence map›Paper›PMID 39754028›Full record

ArticleScientific reports2025

PNMA1 is a novel immune modulator and therapeutic target in hepatocellular carcinoma linked to bile acid metabolism.

Hongyu Chu, Yuezhan Shan, Chengwei Jiang, Yumin Zhong, Zijing Liu, Xuedong Fang, Zhaoying Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hongyu ChuDepartment of Gastrointestinal, Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Yuezhan ShanDepartment of Gastrointestinal, Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Chengwei JiangDepartment of Pathology, China-Japan Union Hospital, Jilin University, Changchun, 130033, Jilin, China.
Yumin ZhongDepartment of Gastrointestinal, Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Zijing LiuDepartment of Gastrointestinal, Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Xuedong FangDepartment of Gastrointestinal, Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, 130033, China. fangxd@jlu.edu.cn.
Zhaoying YangDepartment of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, 130033, China. zyyang@jlu.edu.cn.

Funding

Department of Science and Technology of Jilin Province (20210203215SF, YDZJ202301ZYTS098, ZYY)
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) necessitates innovative prognostic biomarkers and therapeutic targets. By investigating PNMA1 in HCC via the TCGA and GEO databases and our clinical data, we found that its overexpression is associated with worse survival. The relevance of PNMA1 extends to immune factors such as M1 macrophages, CD8

Indexed as

Bile Acids and SaltsCarcinoma, HepatocellularLiver NeoplasmsTumor MicroenvironmentAnimalsBiomarkers, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHep G2 CellsHumansMicePhosphatidylinositol 3-KinasesPrognosisProto-Oncogene Proteins c-aktSignal TransductionBile Acids and SaltsBiomarkers, TumorPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktBioinformatics analysisHepatocellular carcinomaPrognostic biomarkersProteomicsTherapeutic target

Identifiers

PMID39754028
PMCPMC11698831

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.